| Literature DB >> 32631115 |
Qi Zhang1,2, Peipei Yuan1,2, Meng Li1,2, Yang Fu1,2, Ying Hou1,2, Yaping Sun1,2, Liyuan Gao1,2, Yaxin Wei1,2, Weisheng Feng1,2, Xiaoke Zheng1,2.
Abstract
Context: In tEntities:
Keywords: H9c2; anti-myocardial injury; antihypertensive
Mesh:
Substances:
Year: 2020 PMID: 32631115 PMCID: PMC7470167 DOI: 10.1080/13880209.2020.1778043
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Figure 1.Structure of phenylacetamide. The extraction purity is higher than 98%.
Figure 2.Effects of phenylacetamide on cardiac pathological structure, CVF and NOX1 protein expression in SHR rats. The value of the WKY group of NOX1 was set at 1, and the relative value was presented as fold induction to that of the WKY group. Values are expressed as the mean ± SD of 5 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 3.Effects of phenylacetamide on left ventricular systolic function, heart index, NT-proBNP, CKMB, and SBP level in SHR rats. The values of the WKY group of heart index, SBP, LVEDD, LVESD, LVEF and LVFS were set at 1, and the relative values were presented as fold induction to that of the WKY group. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 4.Effects of phenylacetamide on REN and ACE in the hearts of SHR rats. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 5.Effects of phenylacetamide on ET-1 and IL-1β in the hearts of SHR rats. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 6.Effect of phenylacetamide on NOX1 and SOD in the hearts of SHR rats. The value of the WKY group of NOX1 was set at 1, and the relative value was presented as fold induction to that of the WKY group. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 7.Effect of phenylacetamide on MAPK family key proteins in the hearts of SHR rats. The value of the WKY group was set at 1, and the relative value was presented as fold induction to that of the WKY group. Values are expressed as the mean ± SD of 3 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 8.Effect of phenylacetamide on Smad3 the in hearts of SHR rats. The value of the WKY group was set at 1, and the relative value was presented as fold induction to that of the WKY group. Values are expressed as the mean ± SD of 3 samples. *p < 0.05, **p < 0.01 vs. WKY group; #p < 0.05, ##p < 0.01 vs. SHR group.
Figure 9.Effect of phenylacetamide on the survival rate of H9c2 cells. The value of the NC group was set at 1, and the relative value was presented as fold induction to that of the NC group. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. NC group; #p < 0.05, ##p < 0.01 vs. H2O2 group.
Figure 10.Effect of phenylacetamideon SOD levels in H9c2 cells. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. NC group; #p < 0.05, ##p < 0.01 vs. H2O2 group.
Figure 11.Effects of phenylacetamideon ROS levels in H9c2 cells. Figure a. b. c. d. Grey peaks indicate NC group, red peaks indicate H2O2 group, H2O2 + PA-L group, H2O2 + PA-M group and H2O2 + PA-H group, respectively. Values are expressed as the mean ± SD of 3 samples. *p < 0.05, **p < 0.01 vs. NC group; #p < 0.05, ##p < 0.01 vs. H2O2 group.
Figure 12.Effects of phenylacetamide on NOX1 and Smad3 in H9c2 cells. The colour in the circle represents the composite colour of the corresponding target protein (red) and β-tubulin (green). The value of the NC group was set at 1, and the relative value was presented as fold induction to that of the NC group. Values are expressed as the mean ± SD of 6 samples. *p < 0.05, **p < 0.01 vs. NC group; #p < 0.05, ##p < 0.01 vs. H2O2 group.
Figure 13.Mechanism of phenylacetamide on myocardial injury in SHR. The picture on the blue background indicates the pathological manifestation of the SHR, and the red arrow indicates the pathological trend of each indicator. The picture on the pink background indicates changes after phenylacetamide treatment, and the dark blue arrow indicates the trend of improvement in each indicator.